Please assess the completion status of the following clinical trial:

Trial Title: Use of Medication to Improve Weight Loss in Suboptimal Early Responders to Behavioral Treatment

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. BMI ≥ 31 kg/m² (or 28 kg/m2 with obesity-related comorbidity)~2. Age ≥ 21 years and ≤ 70 years~3. Eligible female patients will be:~   * non-pregnant, evidenced by a negative urine pregnancy test~  * non-lactating~  * surgically sterile or postmenopausal, or they will agree to continue to use an accepted method of birth control during the study. Acceptable methods of birth control are: hormonal contraceptives; double barrier method (condom with spermicide or diaphragm with spermicide); intrauterine device; surgical sterility; abstinence; and/or postmenopausal status (defined as at least 2 years without menses).~4. Subjects must:~   * have a primary care provider (PCP) who is responsible for providing routine care~  * understand and be willing to comply with all study-related procedures and agree to participate in the study by giving written informed consent~  * plan to remain in the Philadelphia area for the next 9 months or more~Exclusion Criteria:~1. Pregnant or nursing, or plans to become pregnant in the next 9 months.~2. Uncontrolled hypertension (systolic blood pressure ≥ 140 mm Hg or diastolic blood pressure ≥ 90 mm Hg)~3. Type 1 diabetes~4. Type 2 diabetes~5. A fasting blood glucose \> 126 mg/dL (on second assessment after first elevated value)~6. History of cardiovascular disease (e.g., coronary artery disease, stroke, arrhythmias, congestive heart failure, or heart block greater than first degree~7. Clinically significant hepatic or renal disease~8. Hyperthyroidism~9. Other thyroid disease, not controlled~10. History of malignancy (except for non-melanoma skin cancer) in past 5 years~11. Narrow angle glaucoma~12. Presence or history of marked agitation~13. Current severe major depressive episode (BDI-II score ≥ 29), current active suicidal ideation, or history of suicide attempts within the past 5 years.~14. Any severity of thought or bipolar disorder, or bulimia nervosa.~15. Psychiatric hospitalization within the past 6 months~16. Self-reported alcohol or substance abuse within the past 6 months, including at-risk drinking (current consumption of ≥ 14 alcoholic drinks per week)~17. Past year history of drug abuse~18. Use in the past 2 weeks of monoamine oxidase inhibitors~19. Current use of serotonin-norepinephrine reuptake inhibitors (SNRIs; e.g. venlafaxine, duloxetine, desvenlafaxine, milnacipran, levomilnacipran).~20. Use in past 6 months of medications known to induce significant weight loss (i.e., prescription weight loss medications) or weight gain (e.g., chronic use of oral steroids, second generation antipsychotics)~21. Loss of ≥ 5% of initial body weight within the past 6 months~22. History of (or plans for) bariatric surgery (e.g., roux en y gastric bypass, sleeve gastrectomy, gastric banding), endoscopic intragastric balloon, or aspire assist.~23. Inability to walk 5 blocks comfortably or engage in some other form of aerobic activity (e.g., swimming)~24. Known or suspected allergy to sympathomimetic amines or related products~25. The receipt of any investigational drug within 6 months prior to this trial~26. Previous participation in this trial (e.g., randomized and failed to participate)~27. Changes to any chronic medication (type or dosage) within the past 3 months.~28. Any serious or unstable medical or psychological condition that, in the opinion of the investigator, would compromise the patient's safety or successful participation in the study~Other Therapy: Subjects will be expected to use medications (prescribed by their PCP) to control traditional cardiometabolic risk factors (e.g., hypertension, hypercholesterolemia, etc) and other co-morbid conditions, with the exception of medications listed above under exclusions. In all cases, the subjects' PCP will be asked at the study's outset to keep medication does constant throughout the study, whenever possible. Subjects will be expected to have been on their medication regimen (including the dose) for 3 months prior to beginning the BT program.~To be eligible to participate in the randomized phase of the trial, subjects must also:~1. Complete at least 3 out of 4 treatment sessions during the 4-week BT run-in and attend a randomization visit. Attending an in-person makeup session within one week of a missed visit will count as having attended the run-in visit.~2. Lose \< 2.0% of initial weight during the 4-week BT run-in.~Early BT responders who lose\>=2% during the BT run-in will be offered the same 24-week BT program, but will not receive study medication or be included in the randomized trial.

- Gender: ALL
- Minimum Age: 21 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- Behavioral Treatment + Placebo (Type: ACTIVE_COMPARATOR): All participants will complete an initial 4-week behavioral treatment (BT) run-in. Participants with suboptimal early weight loss in the BT run-in will then be randomly assigned to 24 additional weeks of: 1) BT plus placebo (BT+P); or 2) BT plus medication (BT+M; phentermine 15.0 mg) in a double-blinded fashion. Both treatment groups will continue to attend individual BT sessions and will take a once daily study medication (placebo or phentermine 15.0 mg) for the duration of the intervention period.~Early BT responders identified during the run-in will receive the same 24-week BT program, but will not receive study medication or be included in the randomized trial.
- Behavioral Treatment + Medication (Type: ACTIVE_COMPARATOR): All participants will complete an initial 4-week behavioral treatment (BT) run-in. Participants with suboptimal early weight loss in the BT run-in will then be randomly assigned to 24 additional weeks of: 1) BT plus placebo (BT+P); or 2) BT plus medication (BT+M; phentermine 15.0 mg) in a double-blinded fashion. Both treatment groups will continue to attend individual BT sessions and will take a once daily study medication (placebo or phentermine 15.0 mg) for the duration of the intervention period.~Early BT responders identified during the run-in will receive the same 24-week BT program, but will not receive study medication or be included in the randomized trial.

Based on this trial design, predict the completion outcome and termination type (if applicable).